Buprenorphine Injectable Opioid Abuse Treatment: Will REMS Prevent Misuse?

US FDA worries Indivior's formulation in prefilled syringes could lead to adverse events if patients obtain direct access; advisory committee to consider if REMS requiring administration by healthcare providers is adequate.

Syringes stuck in a dartboard

Indivior PLC's once monthly injectable buprenorphine formulation for the treatment of opioid use disorder seems to get good marks from the US FDA on overall efficacy and safety. But the agency said it is "particularly concerned about the potential risks associated with this product" because it will be available in prefilled syringes with needles attached.

FDA raised potential safety issues with the product, RBP-6000 (buprenorphine injectable), in a briefing document for an Oct. 31...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers